Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study (Q47928939)

6 February 2018

title

Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study (English)

1 reference

6 February 2018

1 reference

1 reference

9

1 reference

6 February 2018

Renaud Snanoudj

R Snanoudj

2

0 references

Markus Büchler

6

M Buchler

1 reference

6 February 2018

Yvon Lebranchu

1

Y Lebranchu

1 reference

6 February 2018

Bruno Hurault de Ligny

5

B Hurault de Ligny

1 reference

6 February 2018

author name string

O Toupance

3

1 reference

6 February 2018

P-F Weestel

4

1 reference

6 February 2018

J-P Rerolle

7

1 reference

6 February 2018

A Thierry

8

1 reference

6 February 2018

J-F Subra

10

1 reference

6 February 2018

P Deteix

11

1 reference

6 February 2018

P Le Pogamp

12

1 reference

6 February 2018

L Finzi

13

1 reference

6 February 2018

I Etienne

14

1 reference

6 February 2018

language of work or name

English

0 references

publication date

5 April 2012

1 reference

6 February 2018

American Journal of Transplantation

published in

1 reference

6 February 2018

volume

12

1 reference

6 February 2018

issue

7

1 reference

6 February 2018

page(s)

1801-1810

1 reference

6 February 2018

A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Outcome of cadaveric renal transplant patients treated for 10 years with cyclosporine: is chronic allograft nephropathy the major cause of late graft loss?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

The adverse impact of cyclosporine on serum lipids in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Inhibitors of the mammalian target of rapamycin and transplant tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

mTOR inhibition: the learning curve in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Sirolimus interferes with iron homeostasis in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF-Four-Year Results of the Postconcept Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1600-6143.2012.04036.X

10.1111/J.1600-6143.2012.04036.X

21 January 2018

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018